Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today we talk about the midsummer chill in the biotech market here in my home town of San Diego. Also, we learn that it was FDA cancer chief Richard Pazdur’s intervention that contributed to the rejection of Replimune’s melanoma drug — not Vinay Prasad.
Biotech winter freezes jobs, but not hope in SoCal
San Diego’s once-sizzling biotech scene is now in a cold snap. It’s left some workers desperate after months of fruitless job hunting for vanishing opportunities, STAT’s Jonathan Wosen writes, while vacancy rates for lab space have surged from 1% to over 22% as companies slash costs.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source link
